• Drug repurposing accelerates COVID-19 treatment development, with several candidates showing clinical efficacy.
• Remdesivir and dexamethasone have demonstrated mortality benefits in hospitalized patients.
• Challenges include drug-drug interactions, optimal dosing, and patient stratification.
• Future research should leverage adaptive trial designs and real-world data to optimize repurposing strategies.